Company intelligence / Profile preview
APIRx Pharmaceuticals
Ijsselstein, Utrecht, Netherlandsapirxpharma.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
At the time of acquisition, APIRx had 22 clinical and pre-clinical programs built around cGMP-produced, naturally extracted cannabinoid APIs; programs addressed multiple large-market indications with an IP portfolio of 19 granted and 23 pending patents. Some programs had completed early clinical or pre-clinical validation[2][7].
- Therapeutic areas
- EndocrinologyOphthalmologyPsychiatryInfectious DiseasesGastroenterologyDermatologyOtherNeurology
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on APIRx Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APIRx Pharmaceuticals.